These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 2338366)

  • 1. International reporting on adverse drug reactions: the CIOMS project. CIOMS ADR Working Group.
    Faich GA; Castle W; Bankowski Z
    Int J Clin Pharmacol Ther Toxicol; 1990 Apr; 28(4):133-8. PubMed ID: 2338366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [International reporting of adverse drug reactions. Final report of CIOMS ADR Working Group].
    Royer RJ; Benichou C
    Therapie; 1991; 46(3):173-8. PubMed ID: 1792648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The international system of drug control].
    Barbadoro E
    Boll Chim Farm; 1990 Mar; 129(3):140-3. PubMed ID: 2245002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Points of view on adverse drug reactions terminology.
    Benichou C; Castle W
    Therapie; 1998; 53(2):145-9. PubMed ID: 9773114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory decisions and consumers.
    Rawlins MD
    Med Toxicol; 1986; 1 Suppl 1():128-9. PubMed ID: 3821428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adverse drug reactions definitions and terminology].
    Rabinovitz H; Berkowitch M; Golik A; Shani S
    Harefuah; 2001 Dec; 140(12):1181-6, 1228. PubMed ID: 11789305
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Detection of side effects. 2: Responsibilities of the pharmaceutical industry, drug commissions, the Federal Health Office and international organizations].
    Gleiter CH; Bieck PR
    Fortschr Med; 1991 Jul; 109(21):429-31. PubMed ID: 1916572
    [No Abstract]   [Full Text] [Related]  

  • 9. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 10. WHO expert committee on specifications for pharmaceutical preparations.
    World Health Organization
    World Health Organ Tech Rep Ser; 2013; (981):i-xi, 1-188. PubMed ID: 23821930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review of Canadian pharmacist involvement in adverse drug reaction reporting.
    Taras-Zasowski KM; Einarson TR
    Can J Hosp Pharm; 1989 Jun; 42(3):105-8, 133. PubMed ID: 10318271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug reaction reporting. Philippine experience.
    Ines Cuyegkeng E
    Med Toxicol; 1986; 1 Suppl 1():99-104. PubMed ID: 3821435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishing requirements for the use of terms for reporting adverse drug reactions (ADR). Consultant, Council for International Organizations of Medical Sciences (CIOMS), World Health Organization.
    Mater Med Pol; 1993; 25(1):45-6. PubMed ID: 8412342
    [No Abstract]   [Full Text] [Related]  

  • 14. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved reporting of adverse drug reactions.
    Kimelblatt BJ; Young SH; Heywood PM; Mandala AR; Gendelman S; Mehl B
    Am J Hosp Pharm; 1988 May; 45(5):1086-9. PubMed ID: 3400650
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adverse drug reactions: a review of relevant factors.
    Ajayi FO; Sun H; Perry J
    J Clin Pharmacol; 2000 Oct; 40(10):1093-101. PubMed ID: 11028248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of standardized screening procedures to identify adverse drug reactions.
    Koch KE
    Am J Hosp Pharm; 1990 Jun; 47(6):1314-20. PubMed ID: 2368724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improving adverse drug reaction reporting in the community setting.
    McCloskey BA
    Med Interface; 1996 May; 9(5):85-7. PubMed ID: 10157690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of serious adverse drug reactions: a proactive pharmacovigilance program (RADAR) vs safety activities conducted by the Food and Drug Administration and pharmaceutical manufacturers.
    Bennett CL; Nebeker JR; Yarnold PR; Tigue CC; Dorr DA; McKoy JM; Edwards BJ; Hurdle JF; West DP; Lau DT; Angelotta C; Weitzman SA; Belknap SM; Djulbegovic B; Tallman MS; Kuzel TM; Benson AB; Evens A; Trifilio SM; Courtney DM; Raisch DW
    Arch Intern Med; 2007 May; 167(10):1041-9. PubMed ID: 17533207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacovigilance: a case of phantom ships and Russian roulette].
    Stricker BH
    Ned Tijdschr Geneeskd; 2002 Jul; 146(27):1258-61. PubMed ID: 12138668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.